We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test to Screen for Fungus May Offer Brand-New Method for Early Cancer Detection

By LabMedica International staff writers
Posted on 07 Oct 2022

Cancer tumors contain multiple species of fungi that differ per tumor type, according to a large study which potentially has implications for the diagnosis and treatment of cancer, as well as for the detection of cancer through a blood test. More...

It complements scientists’ understanding of the interaction between cancer cells and the bacteria that exist in tumors alongside fungi, bacteria that have been shown to affect cancer growth, metastasis and response to therapy.

For the study, researchers at the Weizmann Institute of Science (Rehovot, Israel) and the University of California, San Diego (La Jolla, CA, USA) systematically profiled fungal communities in more than 17,000 tissue and blood samples taken from patients with 35 types of cancer. They found that fungi can be detected in all of these cancer types. Fungi were mostly found “hiding” inside the cancer cells or in immune cells inside the tumors. The study also revealed multiple correlations between the presence of specific fungi in tumors and conditions related to treatment. For example, breast cancer patients who have Malassezia globosa – a fungus found naturally on the skin – in their tumors had a much lower survival rate than those who did not have the fungus. In addition, specific fungi were found to be more prevalent in the breast tumors of older patients than in those of younger ones, in the lung tumors of smokers than in those of nonsmokers and in melanoma tumors that did not respond to immunotherapy than in tumors that did respond to therapy.

These findings suggest that fungal activity is “a new and emerging hallmark of cancer,” according to the researchers. The study, which characterized both the fungi and the bacteria that are present in human tumors, demonstrated that typical “hubs” of fungi and bacteria can be found in tumors. For example, while tumors that contain Aspergillus fungi tend to have specific bacteria in them, other tumors that contain Malassezia fungi tend to have other bacteria in them. These different “hubs” may be important for treatment, as they correlated with both tumor immunity and patient survival. The new paper also explored the presence of fungal and bacterial DNA in human blood.

The existence of fungi in most human cancers “is both a surprise and to be expected,” according to Rob Knight, a professor of Pediatrics, Bioengineering and Computer Science & Engineering at UC San Diego, who coauthored the study. “It is surprising because we don’t know how fungi could get into tumors throughout the body. But it is also expected, because it fits the pattern of healthy microbiomes throughout the body, including the gut, mouth and skin, where bacteria and fungi interact as part of a complex community.”

“The results suggest that measuring microbial DNA in the blood may help in the early detection of cancer, as different microbial DNA signatures can be found in the blood of cancer and noncancer patients,” added Dr. Gregory Sepich-Poore, a former graduate student in Knight’s lab.

Related Links:
Weizmann Institute of Science 
University of California, San Diego 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.